2022 Insights on Cough, Cold and Allergy (Hay Fever) Remedies in the United States: Growth for Cough and Cold Medications Due to the Rise of Respiratory Illnesses – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The report “Remedies for Cough, Cold and Allergy (Hay Fever) in the USA” has been added ResearchAndMarkets.com Offer.
Over a year after FDA approval to move to the OTC market, Astepro allergy nasal spray is now available in retail stores. Astepro is the first and only non-steroid over-the-counter antihistamine nasal spray for 24 hours.
The 0.15 percent strength of the active ingredient azelastine was the only formulation approved for the treatment of rhinitis, and the 0.1 percent formulation for children under the age of six remains a prescription-only product.
The US Cough, Cold, and Allergy (Hay Fever) Remedies report provides a comprehensive view of the size and shape of the market nationally. It offers the latest retail sales data 2017-2021 so you can identify the sectors driving growth. Forecasts up to 2026 show how the market will change.
Product Coverage: Antihistamines/Allergy (Systemic), Combination – Cough, Cold and Allergy (Hay Fever) Remedies, Cough Remedies, Decongestants, Medicated Confectionery, Pediatric Cough, Cold and Allergy Remedies, Throat Preparations.
Data coverage: Market sizes (historical and forecast), company shares, brand shares and sales data.
Why buy this report?
Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market;
Locate growth sectors and identify factors driving change;
Understand the competitive landscape, key players and leading brands of the market;
Use five year forecasts to estimate how the market is likely to develop.
Main topics covered:
REMEDIES FOR Cough, Cold and Allergy (Hay Fever) in USA
KEY DATA RESULTS
Bayer’s Astepro comes to the US market after its successful move from Rx to OTC
Growth in cough and cold medicines due to increase in respiratory diseases
Some consumers are still wary of COVID-19 and are keen to preemptively manage the symptoms
PERSPECTIVES AND OPPORTUNITIES
The potential for longer flu seasons could create greater opportunities for year-round sales
Antihistamines/allergy drugs will perform well over the forecast period
The herbal/natural trend is set to expand, particularly in pediatric products
Table 1 Sales of cough, cold and allergy (hay fever) remedies by category: Value 2017-2022
Table 2 Sales of cough, cold and allergy (hay fever) remedies by category: % value growth 2017-2022
Table 3 NBO company shares in cough, cold and allergy (hay fever) remedies: % value 2018-2022
Table 4 LBN brand shares of cough, cold and allergy (hay fever) remedies: % value 2019-2022
Table 5 Projected Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2022-2027
Table 6 Projected Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2022-2027
US CONSUMER HEALTH
Consumer Health in 2022: The Big Picture
Key Trends 2022
developments in retail
What’s next for consumer health?
Table 7 Consumer spending on health goods and medical services: value 2017-2022
Table 8 Life expectancy at birth 2017-2022
Table 9 Consumer Health Revenue by Category: Value 2017-2022
Table 10 Consumer Health Revenue by Category: % Value Growth 2017-2022
Table 11 Consumer Health NBO Company Shares: % Value 2018-2022
Table 12 Consumer Health LBN brand shares: % value 2019-2022
Table 13 Private label penetration in consumer health by category: % value 2017-2022
Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
Table 15 Distribution of Consumer Health by format and category: % value 2022
Table 16 Consumer Health Projected Sales by Category: Value 2022-2027
Table 17 Projected Consumer Health Revenue by Category: % Value Growth 2022-2027
OTC Registration and Classification
Registration and classification of vitamins and dietary supplements
Self-medication/self-care and preventive medicine
Summary 1 OTC: Switches 2021-2022
For more information about this report, visit https://www.researchandmarkets.com/r/fkdcok